Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin

Atsushi Oda, Yoshitaka Miyakawa, Brian J. Druker, Akaru Ishida, Katsutoshi Ozaki, Hideya Ohashi, Masatoshi Wakui, Makoto Handa, Kiyoaki Watanabe, Shinichiro Okamoto, Yasuo Ikeda

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

Platelet functions such as aggregation and clot retraction are often abnormal in chronic myelogenous leukemia (CML) patients. However, the molecular mechanisms of these altered functions are unknown. As expression of the p210(bcr-abl) oncogene product, a constitutively active tyrosine kinase, is known to have an essential role in the pathogenesis of CML and tyrosine phosphorylation is intimately involved in various aspects of platelet activation, we examined the pattern of protein tyrosine phosphorylation in platelets from 15 CML patients by immunoblotting with a monoclonal antiphosphotyrosine antibody (4G10). Before and after stimulation with thrombin, the only consistent difference between normal and CML platelets was the presence of a tyrosine phosphorylated protein with a relative molecular weight of 39 kD. This tyrosine phosphorylated protein was identified as crkl, an SH2, SH3 containing adapter protein. Thus, as previously demonstrated for neutrophils from CML patients, tyrosine phosphorylation of p39crkl persists in mature platelets. No tyrosine phosphorylation of crkl was detected following stimulation with thrombin in normal platelets. However, crkl became incorporated into the Triton X-100 insoluble residue following thrombin stimulation in a manner dependent on platelet aggregation. Further, we found that crkl is an endogenous substrate for calpain, a protease that may be involved in postaggregation signaling processes. This suggests that crkl may be involved in the reorganization of the cytoskeleton during normal platelet aggregation and its tyrosine phosphorylation in CML platelets may contribute to the abnormal platelet function in CML patients. Finally, we found that thrombopoietin induces tyrosine phosphorylation of crkl in normal platelets and FDCP cells genetically engineered to express human c-Mpl. This suggests that crkl can be phosphorylated by a kinase other than p210(bcr-abl) and that crkl may have a role in signaling by thrombopoietin.

Original languageEnglish
Pages (from-to)4304-4313
Number of pages10
JournalBlood
Volume88
Issue number11
Publication statusPublished - 1996 Dec 1
Externally publishedYes

Fingerprint

Thrombopoietin
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platelets
Tyrosine
Blood Platelets
Phosphorylation
Thrombin
Platelet Aggregation
Agglomeration
Proteins
Clot Retraction
abl Genes
Calpain
Oncogene Proteins
Platelet Activation
Octoxynol
Cytoskeleton
Immunoblotting
Protein-Tyrosine Kinases
Neutrophils

ASJC Scopus subject areas

  • Hematology

Cite this

Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. / Oda, Atsushi; Miyakawa, Yoshitaka; Druker, Brian J.; Ishida, Akaru; Ozaki, Katsutoshi; Ohashi, Hideya; Wakui, Masatoshi; Handa, Makoto; Watanabe, Kiyoaki; Okamoto, Shinichiro; Ikeda, Yasuo.

In: Blood, Vol. 88, No. 11, 01.12.1996, p. 4304-4313.

Research output: Contribution to journalArticle

Oda, A, Miyakawa, Y, Druker, BJ, Ishida, A, Ozaki, K, Ohashi, H, Wakui, M, Handa, M, Watanabe, K, Okamoto, S & Ikeda, Y 1996, 'Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin', Blood, vol. 88, no. 11, pp. 4304-4313.
Oda, Atsushi ; Miyakawa, Yoshitaka ; Druker, Brian J. ; Ishida, Akaru ; Ozaki, Katsutoshi ; Ohashi, Hideya ; Wakui, Masatoshi ; Handa, Makoto ; Watanabe, Kiyoaki ; Okamoto, Shinichiro ; Ikeda, Yasuo. / Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin. In: Blood. 1996 ; Vol. 88, No. 11. pp. 4304-4313.
@article{81ac9f6b013f4bcfa8898aad4946d4dd,
title = "Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin",
abstract = "Platelet functions such as aggregation and clot retraction are often abnormal in chronic myelogenous leukemia (CML) patients. However, the molecular mechanisms of these altered functions are unknown. As expression of the p210(bcr-abl) oncogene product, a constitutively active tyrosine kinase, is known to have an essential role in the pathogenesis of CML and tyrosine phosphorylation is intimately involved in various aspects of platelet activation, we examined the pattern of protein tyrosine phosphorylation in platelets from 15 CML patients by immunoblotting with a monoclonal antiphosphotyrosine antibody (4G10). Before and after stimulation with thrombin, the only consistent difference between normal and CML platelets was the presence of a tyrosine phosphorylated protein with a relative molecular weight of 39 kD. This tyrosine phosphorylated protein was identified as crkl, an SH2, SH3 containing adapter protein. Thus, as previously demonstrated for neutrophils from CML patients, tyrosine phosphorylation of p39crkl persists in mature platelets. No tyrosine phosphorylation of crkl was detected following stimulation with thrombin in normal platelets. However, crkl became incorporated into the Triton X-100 insoluble residue following thrombin stimulation in a manner dependent on platelet aggregation. Further, we found that crkl is an endogenous substrate for calpain, a protease that may be involved in postaggregation signaling processes. This suggests that crkl may be involved in the reorganization of the cytoskeleton during normal platelet aggregation and its tyrosine phosphorylation in CML platelets may contribute to the abnormal platelet function in CML patients. Finally, we found that thrombopoietin induces tyrosine phosphorylation of crkl in normal platelets and FDCP cells genetically engineered to express human c-Mpl. This suggests that crkl can be phosphorylated by a kinase other than p210(bcr-abl) and that crkl may have a role in signaling by thrombopoietin.",
author = "Atsushi Oda and Yoshitaka Miyakawa and Druker, {Brian J.} and Akaru Ishida and Katsutoshi Ozaki and Hideya Ohashi and Masatoshi Wakui and Makoto Handa and Kiyoaki Watanabe and Shinichiro Okamoto and Yasuo Ikeda",
year = "1996",
month = "12",
day = "1",
language = "English",
volume = "88",
pages = "4304--4313",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "11",

}

TY - JOUR

T1 - Crkl is constitutively tyrosine phosphorylated in platelets from chronic myelogenous leukemia patients and inducibly phosphorylated in normal platelets stimulated by thrombopoietin

AU - Oda, Atsushi

AU - Miyakawa, Yoshitaka

AU - Druker, Brian J.

AU - Ishida, Akaru

AU - Ozaki, Katsutoshi

AU - Ohashi, Hideya

AU - Wakui, Masatoshi

AU - Handa, Makoto

AU - Watanabe, Kiyoaki

AU - Okamoto, Shinichiro

AU - Ikeda, Yasuo

PY - 1996/12/1

Y1 - 1996/12/1

N2 - Platelet functions such as aggregation and clot retraction are often abnormal in chronic myelogenous leukemia (CML) patients. However, the molecular mechanisms of these altered functions are unknown. As expression of the p210(bcr-abl) oncogene product, a constitutively active tyrosine kinase, is known to have an essential role in the pathogenesis of CML and tyrosine phosphorylation is intimately involved in various aspects of platelet activation, we examined the pattern of protein tyrosine phosphorylation in platelets from 15 CML patients by immunoblotting with a monoclonal antiphosphotyrosine antibody (4G10). Before and after stimulation with thrombin, the only consistent difference between normal and CML platelets was the presence of a tyrosine phosphorylated protein with a relative molecular weight of 39 kD. This tyrosine phosphorylated protein was identified as crkl, an SH2, SH3 containing adapter protein. Thus, as previously demonstrated for neutrophils from CML patients, tyrosine phosphorylation of p39crkl persists in mature platelets. No tyrosine phosphorylation of crkl was detected following stimulation with thrombin in normal platelets. However, crkl became incorporated into the Triton X-100 insoluble residue following thrombin stimulation in a manner dependent on platelet aggregation. Further, we found that crkl is an endogenous substrate for calpain, a protease that may be involved in postaggregation signaling processes. This suggests that crkl may be involved in the reorganization of the cytoskeleton during normal platelet aggregation and its tyrosine phosphorylation in CML platelets may contribute to the abnormal platelet function in CML patients. Finally, we found that thrombopoietin induces tyrosine phosphorylation of crkl in normal platelets and FDCP cells genetically engineered to express human c-Mpl. This suggests that crkl can be phosphorylated by a kinase other than p210(bcr-abl) and that crkl may have a role in signaling by thrombopoietin.

AB - Platelet functions such as aggregation and clot retraction are often abnormal in chronic myelogenous leukemia (CML) patients. However, the molecular mechanisms of these altered functions are unknown. As expression of the p210(bcr-abl) oncogene product, a constitutively active tyrosine kinase, is known to have an essential role in the pathogenesis of CML and tyrosine phosphorylation is intimately involved in various aspects of platelet activation, we examined the pattern of protein tyrosine phosphorylation in platelets from 15 CML patients by immunoblotting with a monoclonal antiphosphotyrosine antibody (4G10). Before and after stimulation with thrombin, the only consistent difference between normal and CML platelets was the presence of a tyrosine phosphorylated protein with a relative molecular weight of 39 kD. This tyrosine phosphorylated protein was identified as crkl, an SH2, SH3 containing adapter protein. Thus, as previously demonstrated for neutrophils from CML patients, tyrosine phosphorylation of p39crkl persists in mature platelets. No tyrosine phosphorylation of crkl was detected following stimulation with thrombin in normal platelets. However, crkl became incorporated into the Triton X-100 insoluble residue following thrombin stimulation in a manner dependent on platelet aggregation. Further, we found that crkl is an endogenous substrate for calpain, a protease that may be involved in postaggregation signaling processes. This suggests that crkl may be involved in the reorganization of the cytoskeleton during normal platelet aggregation and its tyrosine phosphorylation in CML platelets may contribute to the abnormal platelet function in CML patients. Finally, we found that thrombopoietin induces tyrosine phosphorylation of crkl in normal platelets and FDCP cells genetically engineered to express human c-Mpl. This suggests that crkl can be phosphorylated by a kinase other than p210(bcr-abl) and that crkl may have a role in signaling by thrombopoietin.

UR - http://www.scopus.com/inward/record.url?scp=10544225380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10544225380&partnerID=8YFLogxK

M3 - Article

VL - 88

SP - 4304

EP - 4313

JO - Blood

JF - Blood

SN - 0006-4971

IS - 11

ER -